10x Genomics (NASDAQ:TXG) Trading Up 5.4% – Here’s Why

24 Sep 2026, 16:33 by Tristan Rich · The Markets Daily

Shares of 10x Genomics (NASDAQ:TXG – Get Free Report) shot up 5.4% during mid-day trading on Thursday . The stock traded as high as $78.50 and last traded at $79.7120. 267,092 shares changed hands during trading, a decline of 91% from the average daily volume of 2,855,546 shares. The stock had previously closed at $75.62.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on TXG shares. Weiss Ratings reissued a “sell (d-)” rating on shares of 10x Genomics in a report on Monday. Leerink Partners raised their price target on 10x Genomics from $23.00 to $40.00 and gave the stock a “market perform” rating in a research note on Friday, July 17th. Stifel Nicolaus set a $50.00 price target on 10x Genomics in a research report on Friday, August 7th. UBS Group initiated coverage on 10x Genomics in a research note on Wednesday, September 9th. They issued a “neutral” rating and a $68.00 price objective for the company. Finally, Morgan Stanley increased their price objective on 10x Genomics from $37.00 to $40.00 and gave the company an “equal weight” rating in a report on Friday, August 7th. Five analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average price target of $44.00.

Get Our Latest Stock Report on 10x Genomics

10x Genomics Price Performance

The business’s 50 day simple moving average is $59.11 and its 200 day simple moving average is $38.16. The company has a market capitalization of $10.59 billion, a price-to-earnings ratio of -137.77 and a beta of 2.08.

10x Genomics (NASDAQ:TXG – Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.10. 10x Genomics had a negative net margin of 12.18% and a negative return on equity of 9.33%. The business had revenue of $151.04 million during the quarter, compared to the consensus estimate of $146.67 million. During the same quarter in the prior year, the firm earned $0.28 earnings per share. The business’s quarterly revenue was down 12.7% compared to the same quarter last year. As a group, analysts expect that 10x Genomics will post -0.75 EPS for the current fiscal year.

Insider Activity

In other 10x Genomics news, Director Shehnaaz Suliman sold 2,207 shares of the stock in a transaction that occurred on Monday, August 24th. The stock was sold at an average price of $63.65, for a total transaction of $140,475.55. Following the completion of the sale, the director directly owned 29,515 shares of the company’s stock, valued at approximately $1,878,629.75. This trade represents a 6.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Serge Saxonov sold 10,486 shares of 10x Genomics stock in a transaction that occurred on Wednesday, August 26th. The shares were sold at an average price of $63.69, for a total value of $667,853.34. Following the completion of the transaction, the chief executive officer owned 1,075,349 shares in the company, valued at $68,488,977.81. This trade represents a 0.97% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 148,610 shares of company stock worth $9,314,920 over the last quarter. 8.84% of the stock is owned by insiders.

Institutional Investors Weigh In On 10x Genomics

Hedge funds have recently modified their holdings of the stock. Larson Financial Group LLC grew its position in 10x Genomics by 164.4% in the 4th quarter. Larson Financial Group LLC now owns 2,364 shares of the company’s stock valued at $39,000 after buying an additional 1,470 shares during the last quarter. Fifth Third Bancorp purchased a new position in 10x Genomics during the 1st quarter worth $50,000. Elevation Wealth Partners LLC raised its position in 10x Genomics by 332.3% during the 2nd quarter. Elevation Wealth Partners LLC now owns 1,487 shares of the company’s stock worth $57,000 after buying an additional 1,143 shares during the last quarter. Nykredit A S acquired a new stake in shares of 10x Genomics in the 2nd quarter worth $126,000. Finally, EverSource Wealth Advisors LLC lifted its stake in shares of 10x Genomics by 16.4% in the 1st quarter. EverSource Wealth Advisors LLC now owns 7,186 shares of the company’s stock worth $153,000 after acquiring an additional 1,012 shares during the period. 84.68% of the stock is owned by institutional investors and hedge funds.

10x Genomics Company Profile

(Get Free Report)

10x Genomics, Inc develops life science technology for analyzing biological systems at the single-cell and spatial levels. Its platforms are designed to help researchers study gene expression, genetic variation, cell populations and tissue organization with greater detail than conventional laboratory methods.